Increased malondialdehyde in peripheral blood of patients with congestive heart failure

DOI: 10.1016/s0002-8703(96)90063-0
American Heart Journal, 1996, 131, 146-52.

#	Paper	IF	Citations
183	Oculomotor palsy from minor head trauma: initial sign of intracranial aneurysm. **1994**, 44, 148-50		61
182	Indices of oxidative stress in urine of patients undergoing coronary artery bypass grafting. *Clinical Chemistry and Laboratory Medicine*, **1997**, 35, 737-42	5.9	2
181	Role of lipid peroxidation and the glutathione-dependent antioxidant system in the impairment of endothelium-dependent relaxations with age. **1998**, 123, 113-21		43
180	New targets for heart-failure therapy: endothelin, inflammatory cytokines, and oxidative stress. **1998**, 352 Suppl 1, SI34-8		96
179	Increased oxidative stress in patients with congestive heart failure. **1998**, 31, 1352-6		454
178	Oxidative stress and the pathogenesis of heart failure. **1998**, 16, 665-75, viii-ix		41
177	Elevated levels of 8-iso-prostaglandin F2alpha in pericardial fluid of patients with heart failure: a potential role for in vivo oxidant stress in ventricular dilatation and progression to heart failure. *Circulation*, **1998**, 97, 1536-9	16.7	374
176	Increased oxidative stress in dilated cardiomyopathic heart failure. **1998**, 44, 148-154		67
175	Increased superoxide in heart failure: a biochemical baroreflex gone awry. *Circulation*, **1999**, 100, 216-8	16.7	137
174	Oxidative Stress in Uremia: Impact on Cardiac Disease in Dialysis Patients. **1999**, 12, 91-96		10
173	Oxidative Stress Status in the Transition of Hypertrophy to Heart Failure. *Heart Failure Reviews*, **1999**, 4, 353-360	5	3
172	Oxidative Stress in Heart Failure: Current Understanding and Prospective. *Heart Failure Reviews*, **1999**, 4, 1-10	5	1
171	Oxidative Stress, Vascular Dysfunction and Heart Failure. *Heart Failure Reviews*, **1999**, 4, 1-13	5	6
170	Endothelial Dysfunction in Congestive Heart Failure: Effects of Carvedilol. *Heart Failure Reviews*, **1999**, 4, 53-64	5	1
169	Oxidative Stress and Ventricular Dysfunction in Ischemic Heart Disease. *Heart Failure Reviews*, **1999** , 4, 1-10	5	3
168	Myocardial oxidative stress changes during compensated right heart failure in rats. *Molecular and Cellular Biochemistry*, **1999**, 196, 51-57	4.2	35
167	Potential role of the microvasculature in progression of heart failure. *American Journal of Cardiology*, **1999**, 84, 23L-26L	3	31

166	Biomarkers of free radical damage applications in experimental animals and in humans. **1999**, 26, 202-26		596
165	Changes in plasma oxidative state with age and their influence on contractions elicited by noradrenaline in the rat tail artery. **1999**, 65, 915-24		12
164	Conditioned nutritional requirements and the pathogenesis and treatment of myocardial failure. **2000**, 3, 417-24		39
163	Role of oxidative stress in cardiovascular diseases. **2000**, 18, 655-73		984
162	Relationship of oxidative stress indices to decreased LDL-cholesterol after acute myocardial infarction. **2000**, 33, 423-6		10
161	The effects of L-carnitine treatment on left ventricular function and erythrocyte superoxide dismutase activity in patients with ischemic cardiomyopathy. **2000**, 2, 189-93		26
160	Antioxidative enzymes in human hearts with idiopathic dilated cardiomyopathy. **2000**, 32, 121-30		52
159	Unsaturated aldehydes including 4-OH-nonenal are elevated in patients with congestive heart failure. *Journal of Cardiac Failure*, **2000**, 6, 108-114	3.3	57
158	Relationship between tumor necrosis factor-alpha production and oxidative stress in the failing hearts of patients with dilated cardiomyopathy. **2001**, 37, 2086-92		76
157	Decreased oxidative stress in patients with idiopathic dilated cardiomyopathy one year after immunoglobulin adsorption. **2001**, 38, 178-83		52
156	Antioxidant vitamins attenuate oxidative stress and cardiac dysfunction in tachycardia-induced cardiomyopathy. **2001**, 38, 1734-40		73
155	The isoprostane 8-epi-PGF(2alpha) is a valuable indicator of oxidative injury in human heart valves. **2001**, 10, 241-5		17
154	Dietary and blood antioxidants in patients with chronic heart failure. Insights into the potential importance of selenium in heart failure. **2001**, 3, 661-9		86
153	The oxidative stress hypothesis of congestive heart failure: radical thoughts. **2001**, 120, 2035-46		116
152	A controlled clinical trial of vitamin E supplementation in patients with congestive heart failure. **2001**, 73, 219-24		91
151	Vitamin C inhibits endothelial cell apoptosis in congestive heart failure. *Circulation*, **2001**, 104, 2182-7	16.7	149
150	Oxidative pathways in cardiovascular disease: roles, mechanisms, and therapeutic implications. **2001**, 89, 187-206		166
149	Gene therapeutic approaches to oxidative stress-induced cardiac disease: principles, progress, and prospects. *Antioxidants and Redox Signaling*, **2001**, 3, 433-49	8.4	6

148	Impaired modulation of sympathetic vasoconstriction in contracting skeletal muscle of rats with chronic myocardial infarctions: role of oxidative stress. **2001**, 88, 816-23		70
147	8-iso-prostaglandin F2alpha as a useful clinical biomarker of oxidative stress in ESRD patients. **2002**, 20, 537-42		51
146	Malondialdehyde: a possible marker of ageing. **2002**, 48, 209-14		60
145	Aldosterone-induced inflammation in the rat heart : role of oxidative stress. **2002**, 161, 1773-81		511
144	Role of oxidative stress in myocardial hypertrophy and failure. **2002**, 34, 379-88		448
143	Evidence of increased oxidative stress by simple measurements in patients with dilated cardiomyopathy. **2002**, 62, 463-8		16
142	Vascular dysfunction and heart failure: epiphenomenon or etiologic agent?. *American Heart Journal*, **2002**, 143, 383-90	4.9	42
141	Nutritional abnormalities contributing to cachexia in chronic illness. *International Journal of Cardiology*, **2002**, 85, 23-31	3.2	41
140	[Persistence of oxidative stress after heart transplantation: a comparative study of patients with heart transplant versus chronic stable heart failure]. **2002**, 55, 831-7		11
139	Induction of oxidative stress and disintegrin metalloproteinase in human heart end-stage failure. **2002**, 283, L239-45		42
138	Apoptosis in the left ventricle of chronic volume overload causes endocardial endothelial dysfunction in rats. **2002**, 282, H1197-205		44
137	Lipid peroxidation-derived aldehydes and oxidative stress in the failing heart: role of aldose reductase. **2002**, 283, H2612-9		65
136	Effects of early decrease in oxidative stress after medical therapy in patients with class IV congestive heart failure. *American Journal of Cardiology*, **2002**, 89, 236-9	3	14
135	Free radicals in heart failure: therapeutic targets for old and new drugs. **2002**, 8, 129-30		6
134	Oxidative stress and endothelial dysfunction in heart failure. **2002**, 8, 165-72		44
133	Genetic polymorphisms and oxidative stress in heart failure. **2002**, 8, 157-64, 172		22
132	Cardiac and vascular structure and function are related to lipid peroxidation and metabolism. **2002**, 37, 231-6		36
131	Peripheral limitations of maximal aerobic capacity in patients with chronic heart failure. **2002**, 9, 215-25		22

130	Oxidative stress and antioxidant defense systems in patients after heart transplantation. **2003**, 115, 648-51		10
129	The role of carnitine in normal and altered fatty acid metabolism. **2003**, 41, S4-12		162
128	Relation between oxidative stress, catecholamines, and impaired chronotropic response to exercise in patients with chronic heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. *American Journal of Cardiology*, **2003**, 92, 215-8	3	32
127	Beta-blocker treatment of chronic heart failure: comparison of carvedilol and metoprolol. **2003**, 9, 263-70		6
126	Uremia-related metabolic cardiac risk factors in chronic kidney disease. **2003**, 16, 148-56		30
125	Malondialdehyde inhibits cardiac contractile function in ventricular myocytes via a p38 mitogen-activated protein kinase-dependent mechanism. **2003**, 139, 1310-6		35
124	Increased lipid peroxidation during long-term intervention with high doses of n-3 fatty acids (PUFAs) following an acute myocardial infarction. **2003**, 57, 793-800		47
123	Neurohormones and oxidative stress in nonischemic cardiomyopathy: relationship to survival and the effect of treatment with amlodipine. *American Heart Journal*, **2003**, 146, 291-7	4.9	30
122	Plasma thioredoxin levels and platelet aggregability in patients with acute myocardial infarction. *American Heart Journal*, **2003**, 146, 465-71	4.9	42
121	Influence of vitamin C on baroreflex sensitivity in chronic heart failure. **2003**, 41, 1240-5		45
120	Aldosteronism and peripheral blood mononuclear cell activation: a neuroendocrine-immune interface. **2003**, 93, e124-35		92
119	Aldosteronism: an immunostimulatory state precedes proinflammatory/fibrogenic cardiac phenotype. **2003**, 285, H813-21		92
118	Congestive heart failure in patients with chronic kidney disease and on dialysis. *American Journal of the Medical Sciences*, **2003**, 325, 179-93	2.2	39
117	Failing atrial myocardium: energetic deficits accompany structural remodeling and electrical instability. **2003**, 284, H1313-20		74
116	Redox modulation of the inotropic response to dobutamine is impaired in patients with heart failure. **2004**, 286, H789-95		14
115	Paradox of circulating advanced glycation end product concentrations in patients with congestive heart failure and after heart transplantation. **2004**, 90, 1269-74		12
114	Oxidative stress during myocardial ischaemia and heart failure. **2004**, 10, 1699-711		152
113	Endothelial dysfunction and nitric oxide enhancing therapy: a new approach to the treatment of heart failure. **2004**, 10, 237-42		1

112	Inhibition of cardiac myocyte contraction by 4-hydroxy-trans-2-nonenal. **2004**, 4, 21-8		17
111	Regulation of matrix metalloproteinases by cytokines and reactive oxygen/nitrogen species in the myocardium. *Heart Failure Reviews*, **2004**, 9, 43-51	5	171
110	Antioxidant and oxidative stress changes in experimental cor pulmonale. *Molecular and Cellular Biochemistry*, **2004**, 260, 21-9	4.2	57
109	Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. **2004**, 351, 2049-57		1299
108	Alteration of plasma total F2-isoprostanes before and after hemodialysis in end-stage renal disease patients. **2004**, 70, 475-8		9
107	Effect of systemic vitamin C on free fatty acid-induced lipid peroxidation. **2004**, 30, 433-9		15
106	Strategies to reduce oxidative stress in cardiovascular disease. **2004**, 106, 219-34		152
105	Tachycardia-induced cardiomyopathy: a review of literature. **2005**, 28, 710-21		87
104	Reduced oxidative stress in parallel to improved cardiac performance one year after selective removal of anti-beta 1-adrenoreceptor autoantibodies in patients with idiopathic dilated cardiomyopathy: data of a preliminary study. **2005**, 20, 137-42		14
103	Effects of carvedilol on oxidative stress and chronotropic response to exercise in patients with chronic heart failure. **2005**, 7, 1033-9		29
102	Role of Coronary Microvascular Endothelial Dysfunction in the Development of Heart Failure. **2005**, 1, 247-253		
101	Enhanced oxidative stress in coronary heart disease and chronic heart failure as indicated by an increased 8-epi-PGF(2alpha). **2005**, 7, 167-72		44
100	Nutrients, Stress, and Medical Disorders. **2005**,		5
99	Aldosteronism and a proinflammatory vascular phenotype: role of Mg2+, Ca2+, and H2O2 in peripheral blood mononuclear cells. *Circulation*, **2005**, 111, 51-7	16.7	81
98	Antioxidants and Cardiovascular Disease. *Developments in Cardiovascular Medicine*, **2006**,		3
97	Energy deficiency in the failing heart: linking increased reactive oxygen species and disruption of oxidative phosphorylation rate. **2006**, 1757, 543-52		59
96	Conditioned Nutritional Requirements of the Failing Heart. **2006**, 341-352		
95	Use of Biomarkers of Oxidative Stress in Human Studies. **2006**, 1045-1076		1

94	Secondary hyperparathyroidism and hypovitaminosis D in African-Americans with decompensated heart failure. *American Journal of the Medical Sciences*, **2006**, 332, 112-8	2.2	61
93	Micronutrients and their supplementation in chronic cardiac failure. An update beyond theoretical perspectives. *Heart Failure Reviews*, **2006**, 11, 65-74	5	35
92	Oxidative stress in cardiovascular disease: a new avenue toward future therapeutic approaches. **2006**, 1, 151-9		28
91	Peroxisome proliferator-activated receptor delta (PPARdelta) activation protects H9c2 cardiomyoblasts from oxidative stress-induced apoptosis. **2006**, 69, 440-9		79
90	Oxidative stress causes heart failure with impaired mitochondrial respiration. **2006**, 281, 33789-801		168
89	Cranberry juice increases antioxidant status without affecting cholesterol homeostasis in orchidectomized rats. **2007**, 10, 49-53		20
88	Exercise-induced increase in lipid peroxidation in patients with chronic heart failure: relation to exercise intolerance. **2007**, 108, 307-13		8
87	Aminothiol redox alterations in patients with chronic heart failure of ischaemic or non-ischaemic origin. **2007**, 8, 1024-8		7
86	Coenzyme Q10 in cardiovascular disease. **2007**, 7 Suppl, S154-67		104
85	Blood glutathione as independent marker of lipid peroxidation in heart failure. *International Journal of Cardiology*, **2007**, 117, 45-50	3.2	32
84	Rapid and Simple Determination of Plasma and Erythrocyte MDA Levels in Prostate Cancer Patients by a Validated HPLC Method. **2007**, 30, 2435-2444		3
83	Mechanisms by which low-intensity ultrasound improve tolerance to ischemia-reperfusion injury. *Ultrasound in Medicine and Biology*, **2007**, 33, 663-71	3.5	13
82	African American heart failure trial: role of endothelial dysfunction and heart failure in African Americans. *American Journal of Cardiology*, **2007**, 99, 3D-6D	3	16
81	Selective type 1 angiotensin II receptor blockade attenuates oxidative stress and regulates angiotensin II receptors in the canine failing heart. *Molecular and Cellular Biochemistry*, **2008**, 317, 97-104	4.2	12
80	Uncoupling proteins in heart failure. *Current Heart Failure Reports*, **2008**, 5, 75-9	2.8	36
79	Circulating white blood cells and platelets amplify oxidative stress in heart failure. *Nature Clinical Practice Cardiovascular Medicine*, **2008**, 5, 811-20		50
78	Expression of ubiquitin in peripheral inflammatory cells from patients with coronary artery disease. *Journal of International Medical Research*, **2008**, 36, 1227-34	1.4	6
77	Cinacalcet and the prevention of secondary hyperparathyroidism in rats with aldosteronism. *American Journal of the Medical Sciences*, **2008**, 335, 105-10	2.2	29

76	Expression of heme oxygenase-1, hypoxia inducible factor-1alpha, and ubiquitin in peripheral inflammatory cells from patients with coronary heart disease. *Clinical Chemistry and Laboratory Medicine*, **2009**, 47, 327-33	5.9	13
75	Gln(27)-->Glubeta(2)-adrenergic receptor polymorphism in heart failure patients: differential clinical and oxidative response to carvedilol. *Basic and Clinical Pharmacology and Toxicology*, **2009**, 104, 374-8	3.1	19
74	Endothelial dysfunction in African-Americans. *International Journal of Cardiology*, **2009**, 132, 157-72	3.2	19
73	Antioxidants in the prevention of myocardial ischemia/reperfusion injury. *Expert Review of Clinical Pharmacology*, **2009**, 2, 673-95	3.8	17
72	Biomarkers of oxidative stress in heart failure. *Heart Failure Clinics*, **2009**, 5, 561-77	3.3	33
71	Congestive heart failure: where homeostasis begets dyshomeostasis. *Journal of Cardiovascular Pharmacology*, **2010**, 56, 320-8	3.1	29
70	Coenzyme Q10 for heart failure. **2010**,		1
69	Serum oxidizability potential is associated with age and exercise test results. *European Review of Aging and Physical Activity*, **2010**, 7, 37-41	6.5	
68	Model mice for tissue-specific deletion of the manganese superoxide dismutase gene. *Geriatrics and Gerontology International*, **2010**, 10 Suppl 1, S70-9	2.9	44
67	Reactive oxygen/nitrogen species and the myocardial cell homeostasis: an ambiguous relationship. *Antioxidants and Redox Signaling*, **2010**, 13, 1899-910	8.4	13
66	Cellular and molecular pathways to myocardial necrosis and replacement fibrosis. *Heart Failure Reviews*, **2011**, 16, 23-34	5	39
65	Air pollution and circulating biomarkers of oxidative stress. *Air Quality, Atmosphere and Health*, **2011**, 4, 37-52	5.6	108
64	Contribution of catecholamine reactive intermediates and oxidative stress to the pathologic features of heart diseases. *Current Medicinal Chemistry*, **2011**, 18, 2272-314	4.3	77
63	Diminished antioxidant activity of high-density lipoprotein-associated proteins in systolic heart failure. *Circulation: Heart Failure*, **2011**, 4, 59-64	7.6	52
62	Old and new biomarkers of oxidative stress in heart failure. *Drug Discovery Today: Therapeutic Strategies*, **2012**, 9, e189-e198		4
61	Nitric oxide modulation as a therapeutic strategy in heart failure. *Heart Failure Clinics*, **2012**, 8, 255-72	3.3	11
60	Nutritional intake and oxidative stress in chronic heart failure. *Nutrition, Metabolism and Cardiovascular Diseases*, **2012**, 22, 376-82	4.5	57
59	Markers of oxidative damage and antioxidant enzyme activities as predictors of morbidity and mortality in patients with chronic heart failure. *Journal of Cardiac Failure*, **2012**, 18, 493-501	3.3	42

58	Dietary chlorophyll metabolites catalyze the photoreduction of plasma ubiquinone. *Photochemistry and Photobiology*, **2013**, 89, 310-3	3.6	4
57	Oxidative stress markers and C-reactive protein are related to severity of heart failure in patients with dilated cardiomyopathy. *Mediators of Inflammation*, **2014**, 2014, 147040	4.3	27
56	Oxidative stress status increase in patients with nonischemic heart failure. *Medical Principles and Practice*, **2014**, 23, 532-7	2.1	12
55	Coenzyme Q10 for heart failure. *The Cochrane Library*, **2014**, CD008684	5.2	43
54	Circulating levels of linoleic acid and HDL-cholesterol are major determinants of 4-hydroxynonenal protein adducts in patients with heart failure. *Redox Biology*, **2014**, 2, 148-55	11.3	20
53	Uric Acid, Oxidative Stress and Inflammation in Chronic Heart Failure with Reduced Ejection Fraction. *Romanian Journal of Laboratory Medicine*, **2015**, 23, 397-406	0.3	6
52	Oxidative stress and inflammatory markers - the future of heart failure diagnostics?. *Kardiochirurgia I Torakochirurgia Polska*, **2015**, 12, 145-9	0.3	15
51	Manganese superoxide dismutase and oxidative stress modulation. *Advances in Clinical Chemistry*, **2015**, 68, 87-130	5.8	153
50	Oxidative Stress and Inflammation in Cardiovascular Diseases: Two Sides of the Same Coin. **2015**, 259-278		
49	Pre-treatment with □-tocopherol and Terminalia arjuna ameliorates, pro-inflammatory cytokines, cardiac and apoptotic markers in myocardial infracted rats. *Redox Report*, **2015**, 20, 49-59	5.9	8
48	An experimental demonstration that early-life competitive disadvantage accelerates telomere loss. *Proceedings of the Royal Society B: Biological Sciences*, **2015**, 282, 20141610	4.4	100
47	Free Radicals in Human Health and Disease. **2015**,		6
46	Unbalanced Oxidant-Antioxidant Status: A Potential Therapeutic Target for Coronary Chronic Total Occlusion in Very Old Patients. *Oxidative Medicine and Cellular Longevity*, **2016**, 2016, 4910829	6.7	1
45	Vanillin mitigates potassium bromate-induced molecular, biochemical and histopathological changes in the kidney of adult mice. *Chemico-Biological Interactions*, **2016**, 252, 102-13	5	14
44	Markers of oxidative stress in dogs with heart failure. *Journal of Veterinary Diagnostic Investigation*, **2017**, 29, 636-644	1.5	12
43	Serum paraoxonase activity in patients with ischaemic and nonischaemic dilated cardiomyopathy. *Acta Cardiologica*, **2018**, 73, 85-90	0.9	3
42	Ablation of the stress protease OMA1 protects against heart failure in mice. *Science Translational Medicine*, **2018**, 10,	17.5	41
41	Effects of Diesel Exhaust on Cardiovascular Function and Oxidative Stress. *Antioxidants and Redox Signaling*, **2018**, 28, 819-836	8.4	33

40	Selenium supplementation lowers insulin resistance and markers of cardio-metabolic risk in patients with congestive heart failure: a randomised, double-blind, placebo-controlled trial. *British Journal of Nutrition*, **2018**, 120, 33-40	3.6	19
39	Malondialdehyde and Uric Acid as Predictors of Adverse Outcome in Patients with Chronic Heart Failure. *Oxidative Medicine and Cellular Longevity*, **2019**, 2019, 9246138	6.7	5
38	Effects of nucleotide supplementation to corn□oybean meal-based diet on growth performance, fecal microflora, and blood profiles of sows and performance of suckling piglets. *Canadian Journal of Animal Science*, **2019**, 99, 754-763	0.9	3
37	Biomarkers in heart failure: the past, current and future. *Heart Failure Reviews*, **2019**, 24, 867-903	5	48
36	Lipoxidation in cardiovascular diseases. *Redox Biology*, **2019**, 23, 101119	11.3	40
35	Effect of chronic kidney disease in ischemic cardiomyopathy: Long-term follow-up - REVISION-DM2 trial. *Medicine (United States)*, **2019**, 98, e14692	1.8	
34	Changes of inflammatory and oxidative stress biomarkers in dogs with different stages of heart failure. *BMC Veterinary Research*, **2020**, 16, 433	2.7	2
33	Antioxidant defence and oxidative stress markers in cats with asymptomatic and symptomatic hypertrophic cardiomyopathy: a pilot study. *BMC Veterinary Research*, **2020**, 16, 26	2.7	5
32	Lipid Peroxidation in Atherosclerotic Cardiovascular Diseases. *Antioxidants and Redox Signaling*, **2021**, 34, 49-98	8.4	14
31	Coenzyme Q10 for heart failure. *The Cochrane Library*, **2021**, 2021,	5.2	2
30	Serum Sulfhydryl Groups, Malondialdehyde, Uric Acid, and Bilirubin as Predictors of Adverse Outcome in Heart Failure Patients due to Ischemic or Nonischemic Cardiomyopathy. *Oxidative Medicine and Cellular Longevity*, **2021**, 2021, 6693405	6.7	2
29	Oxidative Stress as A Mechanism for Functional Alterations in Cardiac Hypertrophy and Heart Failure. *Antioxidants*, **2021**, 10,	7.1	12
28	Oxidative Stress in Heart Failure. **2006**, 437-450		1
27	Effects of Captopril on Myocardial Oxidative Stress Changes in Post-Mi Rats. *Progress in Experimental Cardiology*, **1998**, 527-536		1
26	Poor acute outcome in congestive heart failure is associated with increases in the plasma static oxidation-reduction potentials (sORP) in men but not in women. *Redox Report*, **2017**, 22, 534-541	5.9	3
25	Effects of prolonged propranolol treatment on left ventricular remodeling and oxidative stress after myocardial infarction in rats. *Journal of Cardiovascular Pharmacology*, **2000**, 35, 806-13	3.1	14
24	Right and left myocardial antioxidant responses during heart failure subsequent to myocardial infarction. *Circulation*, **1997**, 96, 2414-20	16.7	184
23	Ellagic acid improves electrocardiogram waves and blood pressure against global cerebral ischemia rat experimental models. *Electronic Physician*, **2015**, 7, 1153-62	1.8	16

22	Chronic heart failure is characterized by altered mitochondrial function and structure in circulating leucocytes. *Oncotarget*, **2018**, 9, 35028-35040	3.3	10
21	Interactions biophysiques membranaires de l???amlodipine et propri??t??s antioxydantes. *Drugs*, **2000**, 59, 9-16	12.1	9
20	Serum oxidizability potential of ischemic heart disease patients is associated with exercise test results and disease severity. *World Journal of Cardiology*, **2009**, 1, 46-50	2.1	2
19	The Role of Neurohormonal Systems, Inflammatory Mediators and Oxydative Stress in Cardiomyopathy.		0
18	Oxidative Stress and Use of Antioxidants in Patients with Congestive Heart Failure. *Developments in Cardiovascular Medicine*, **2000**, 211-224		
17	Role of NO in Myocardial Injury Induced by Oxidative Stress: Ischemia, Myocarditis, Cardiomyopathy, and Heart Failure. **2000**, 81-87		
16	Role of Oxidative Stress, Cytokines, and Apoptosis in Myocardial Dysfunction. *Developments in Cardiovascular Medicine*, **2000**, 193-209		
15	A Rationale for Antioxidant Use in Cardiovascular Disease. *Developments in Cardiovascular Medicine*, **2000**, 145-159		
14	Oxidative stress in heart failure. **2000**, 262-284		1
13	Micronutrients and Cardiovascular Disease. **2003**,		
12	Role of Reactive Oxygen Species in the Regulation of Cardiac Myocyte Phenotype. *Progress in Experimental Cardiology*, **2004**, 51-57		
11	Indicators of oxidative stress and plasma antioxidative enzyme activity in patients with different stages of heart failure. *Srce I Krvni Sudovi*, **2011**, 30, 35-42		
10	Oxidative and Nitrosative Stress in Heart Failure. **2011**, 185-197		
9	Myocardial oxidative stress changes during compensated right heart failure in rats. **1999**, 51-57		
8	A Cross-Sectional Study on Assessment of Oxidative Stress in Coronary Heart Disease Patients in Bangladesh. *World Journal of Cardiovascular Diseases*, **2019**, 09, 331-342	0	1
7	Use of Antioxidants in Patients with Congestive Heart Failure. **2006**, 451-476		
6	Reduction in oxidative stress and modulation of heart failure subsequent to myocardial infarction in rats. *Experimental and Clinical Cardiology*, **2005**, 10, 146-53		9
5	Myocardial oxidative stress changes during compensated right heart failure in rats. *Molecular and Cellular Biochemistry*, **1999**, 196, 51-7	4.2	9

4	Future scope and challenges for congestive heart failure: Moving towards development of pharmacotherapy. *Canadian Journal of Physiology and Pharmacology*,	2.4	0
3	Ferroptosis: The Potential Target in Heart Failure with Preserved Ejection Fraction. **2022**, 11, 2842		1
2	Advances in congestive heart failure biomarkers. **2022**,		0
1	Novel Oxidative Stress Biomarkers with Risk Prognosis Values in Heart Failure. **2023**, 11, 917		0